3/5/2008

Roche Holding and GlaxoSmithKline PLC -- manufacturers of Tamiflu and Relenza, respectively -- have placed new warnings regarding delirium and abnormal psychiatric behavior on the labels of their influenza medications. The FDA has reviewed reports of neuropsychiatric problems in some patients, primarily in Japan. The drugmakers, however, said on the labels that their drugs' link to these adverse reactions "has not been established."

Related Summaries